Select Language

AI社区

公开数据集

CiPA ECG Validation Study Database

CiPA ECG Validation Study Database

3G
319 浏览
0 喜欢
0 次下载
0 条讨论
Medical 2D Box,Audio

ECG effects of ranolazine, verapamil, lopinavir+ritonavir, chloroquine, dofetilide, diltiazem, and dofetilide+diltiazem......

数据结构 ? 3G

    Data Structure ?

    * 以上分析是由系统提取分析形成的结果,具体实际数据为准。

    README.md

    ECG effects of ranolazine, verapamil, lopinavir+ritonavir, chloroquine, dofetilide, diltiazem, and dofetilide+diltiazem in a small sample size clinical study. The ECGCIPA database contains multi-channel ECG recordings of 60 subjects participating in the CiPA ECG validation study.

    Experimental Method

    This study assessed whether exposure response analysis of the electrocardiographic QTc and J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that drugs that predominantly block the potassium channel encoded by the human ether-a-go-go-related gene (hERG) with approximately equipotent late sodium and/or calcium block ("balanced ion channel" drugs) do not cause J-Tpeakc prolongation and that drugs that predominantly block hERG without late sodium or L-type calcium current block ("predominant hERG" drugs) cause QTc prolongation.

    This clinical study consists of 2 parts: a 50-subject parallel part (Part 1) and a 10-subject crossover part (Part 2).

    • Part 1 was a double-blind, randomized, placebo-controlled, 1 period parallel designed to assess the effect of 4 marketed drugs (ranolazine, verapamil, lopinavir+ritonavir, and chloroquine) and 1 placebo on the QTc and J-Tpeakc intervals in 50 healthy subjects. A parallel design similar to a single or multiple ascending dose (SAD/MAD) Phase 1 study was used and resulted in each study drug being administered to 10 subjects, and placebo to 10 subjects, in 1 period of 3 consecutive days to achieve low and high drug exposure. Subjects 1001-1050 participated in part 1 of the study.
    • Part 2 was a double-blind, randomized, 2-period crossover design to assess the effect of hERG block (dofetilide) versus calcium block (diltiazem) on the QTc and J-Tpeakc intervals in 10 healthy subjects on Days 1, 2, and 3 (Period 1) and Days 8, 9, and 10 (Period 2). Subjects 2001-2010 participated in part 2 of the study.

    More details about the rationale and study design are described in [1], which includes the study protocol and statistical analysis plan in the on-line supplement. Detailed ECG methods are described in [2]. Finally, study results are available in [3].

    ClinicalTrials.gov identifier: NCT03070470 (https://clinicaltrials.gov/ct2/show/NCT03070470)

    Files

    • raw (5749 records, no annotations): original extracted 10-second 12-lead ECG segments organized in subdirectories named after the subject identifier or USUBJID in the clinical data sets.
    • medians (5749 annotated records):
      • derived representative median beats of the raw ECG segments.
      • semi-automatic annotations of each median beat in the vector magnitude lead: P onset, QRS onset, QRS offset, T peak, secondary T peak (if present]) and T offset. The annotations are stored in standard MIT annotation format, with annotator extension .atr.
    • The file ecgcipa_metadata.docx describes the columns of the clinical data sets:
      • ADEG (adeg.csv): This is a one record per subject per parameter per analysis period per analysis visit per analysis time point data set that contains a comprehensive set of variables pertaining to the subject and their quantitative measures in the electrocardiogram (ECG).
      • ADPC (adpc.csv): This is a one record per subject per pharmacokinetic (PK) parameter per analysis period per analysis visit per analysis time point data set that contains a comprehensive set of variables pertaining to the subject and their quantitative pharmacokinetic measures.
      • ADSL (adsl.csv): Subject-level analysis dataset containing one record per subject.
      • ADDM (addm.csv): This is a one record per subject per parameter data set with additional demographic and vital signs information collected at check-in.

    The ecgcipa.zip file contains all of the WFDB ecg signal and annotation files.

    References

    1. Vicente J, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, Matta MK, Li Z, Liu J, Garnett C, Stockbridge N, Zineh I, Strauss DG. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the CiPA Initiative and Design of a Prospective Clinical Validation Study. Clin Pharmacol Ther 2018 Jan; 103(1):54-66. doi: 10.1002/cpt.896
    2. Vicente J. Update on the ECG Component of the CiPA Initiative. J Electrocardiol 2018 Nov; 51(6): S98-S12. doi: 10.1016/j.jelectrocard.2018.08.003
    3. Vicente J, Zusterzeel R, Johannesen L, Ochoa-Jimenez R, Mason J, Sanabria C, Kemp S, Sager P, Patel V, Matta MK, Liu J, Florian J, Garnett C, Stockbridge N, Strauss DG. Assessment of Multi-Ion Channel Block in a Phase-I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. Clin Pharmacol Ther. doi: 10.1002/cpt.1303

    When using this resource, please cite the original publication:

    Vicente J, Zusterzeel R, Johannesen L, Ochoa-Jimenez R, Mason J, Sanabria C, Kemp S, Sager P, Patel V, Matta MK, Liu J, Florian J, Garnett C, Stockbridge N, Strauss DG. Assessment of Multi-Ion Channel Block in a Phase-I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study.. Clin Pharmacol Ther. doi: 10.1002/cpt.1303.

    Please include the standard citation for PhysioNet: (show more options)
    Goldberger, A., Amaral, L., Glass, L., Hausdorff, J., Ivanov, P. C., Mark, R., ... & Stanley, H. E. (2000). PhysioBank, PhysioToolkit, and PhysioNet: Components of a new research resource for complex physiologic signals. Circulation [Online]. 101 (23), pp. e215–e220.



    ×

    帕依提提提温馨提示

    该数据集正在整理中,为您准备了其他渠道,请您使用

    注:部分数据正在处理中,未能直接提供下载,还请大家理解和支持。
    暂无相关内容。
    暂无相关内容。
    • 分享你的想法
    去分享你的想法~~

    全部内容

      欢迎交流分享
      开始分享您的观点和意见,和大家一起交流分享.
    所需积分:10 去赚积分?
    • 319浏览
    • 0下载
    • 0点赞
    • 收藏
    • 分享